The expression and ratio of CD20 and CD59 molecules vary substantially in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia patient-derived cell lines [42,43,44] and it will be extremely interesting to discover, to what extent the novel anti-CD20/CD59 construct can enhance CDC effect of RX for such diverse spectrum of cells. Here, CD59 is linked to non-Hodgkin lymphoma.